Nearly three months into its pivotal study of lead immunotherapy candidate rindopepimut in a subset of glioblastoma multiforme (GBM) patients, Celldex Therapeutics Inc. is pulling in about $40.4 million in a public offering to help support that study and advance earlier pipeline programs.